Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NSD2 | O96028 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CASR | P41180 | 11/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26022766 | 0.82 | MAPT (0.40) | MAPTKDM4ENSD2ALDH1A1 | |
| SCHEMBL23717463 | 0.77 | CASR (0.34) | ALDH1A1CASR | |
| SCHEMBL22923316 | 0.74 | MAPT (0.39) | MAPTKDM4ENSD2ALDH1A1 | |
| SCHEMBL21871679 | 0.73 | MAPT (0.38) | MAPTKDM4ENSD2ALDH1A1 | |
| SCHEMBL21938497 | 0.72 | ALDH1A1 (0.51) | MAPTKDM4ENSD2ALDH1A1 | |
| SCHEMBL12709597 | 0.71 | MAPT (0.58) | MAPTKDM4ENSD2ALDH1A1 | |
| SCHEMBL19619606 | 0.69 | KEAP1 (0.40) | MAPTKDM4EALDH1A1 | |
| SCHEMBL24345425 | 0.67 | IRAK4 (0.36) | CASR | |
| SCHEMBL29304344 | 0.65 | — | — | |
| SCHEMBL29304382 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228489-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | VANDERBILT UNIVERSITY | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228489-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | CHRM1, CHRM3, CHRM2 | MAPT 337/4885KDM4E 2149/4885NSD2 1378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.